October 6, 2026 October 6, 2026Categories Press ReleasesPress Release: Major HER2+ breast cancer trial identifies factors associated with pathologic complete response to less intensive chemotherapy
September 23, 2026 September 23, 2026Categories Press ReleasesPress Release: ECOG-ACRIN launches a landmark trial to evaluate chemotherapy benefit in high-risk early-stage breast cancer
September 17, 2026 September 17, 2026Categories Press ReleasesPress Release: A new AI-powered test offers more accurate prediction of breast cancer recurrence risk
July 23, 2026 July 23, 2026Categories Press ReleasesPress Release: Proactive support to quit tobacco use during cancer treatment doubles quit rates in a nationwide trial
July 15, 2026 July 15, 2026Categories Press ReleasesPress Release: ECOG-ACRIN ENDURANCE trial findings published in the New England Journal of Medicine provide the first randomized evidence on the optimal duration of lenalidomide maintenance for patients with newly diagnosed multiple myeloma
June 10, 2026 June 10, 2026Categories Press ReleasesPress Release: Elsa Anagnostou, Jordan Berlin, and Olisaemeka Ogbue receive ECOG-ACRIN 2026 scientific leadership and mentorship awards
May 21, 2026 May 21, 2026Categories Press ReleasesPress Release: Guide to ECOG-ACRIN cancer research at ASCO 2026
May 19, 2026 May 19, 2026Categories Announcements Press ReleasesPress Release: TAILORx and RxPONDER trials shift to a discovery platform for analyzing breast cancer recurrence using advanced tumor profiling and AI
March 19, 2026 March 19, 2026Categories Press ReleasesPress Release: ECOG-ACRIN completes enrollment for 600-patient clinical trial focused on frontline treatment for advanced melanoma
